Sagespring Wealth Partners LLC Decreases Stock Position in Becton, Dickinson and Company $BDX

Sagespring Wealth Partners LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 16.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,418 shares of the medical instruments supplier’s stock after selling 661 shares during the period. Sagespring Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $589,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after acquiring an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Becton, Dickinson and Company by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock valued at $707,872,000 after buying an additional 37,733 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 1,838 shares of company stock valued at $348,392. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.9%

NYSE:BDX opened at $185.08 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $53.05 billion, a price-to-earnings ratio of 33.29, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The business has a fifty day moving average price of $190.69 and a 200-day moving average price of $185.17.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.